Comparative Pharmacology
Head-to-head clinical analysis: DIPHENYLAN SODIUM versus MILONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENYLAN SODIUM versus MILONTIN.
DIPHENYLAN SODIUM vs MILONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.
100 mg orally every 8 hours
Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.
None Documented
None Documented
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Terminal elimination half-life is 6–8 hours in adults, longer in children (8–12 hours) and elderly (10–14 hours); clinical context: requires multiple daily dosing to maintain therapeutic levels.
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
Primarily hepatic metabolism and renal excretion; approximately 60% of a dose is excreted in urine as conjugated metabolite (phensuximide glucuronide), with 15% as unchanged drug; 20% eliminated in feces.
Category C
Category C
Antiepileptic
Antiepileptic